Genotype dependent QSAR for HIV-1 protease inhibition

Journal of Medicinal Chemistry

Volumn 48, Issue 6, 2005, Pages 2115-2120

  Boutton, Carlo W ^a   De Bondt, Hendrik L ^a   De Jonge, Marc R ^b  

^a TIBOTEC BVBA   (Belgium)

^b Center for Molecular Design   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; RNA DIRECTED DNA POLYMERASE;

ANTIBIOTIC RESISTANCE; ARTICLE; CONTROLLED STUDY; GENE MUTATION; GENETIC VARIABILITY; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN IMMUNODEFICIENCY VIRUS 1; MATHEMATICAL ANALYSIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN INTERACTION; PROTEINASE INHIBITION; QUANTITATIVE STRUCTURE ACTIVITY RELATION; STRUCTURAL GENE;

CARBAMATES; DRUG RESISTANCE, VIRAL; GENOTYPE; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; MUTATION; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; SULFONAMIDES; THERMODYNAMICS;

EID: 15444375057     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm049596h     Document Type: Article

References (37)

1. Shafer, R. W.; Kantor, R.; Gonzales, M. J. The genetic basis of HIV-1 resistance to reverse transcriptase and protease inhibitors. AIDS Rev. 2000, 2, 211-228.
2. Perrin, L.; Telenti, A. HIV treatment failure: Testing for HIV resistance in clinical practice. Science 1998, 280, 1871-1873.
3. Vandamme, A. M.; Van Laethem, K.; De Clerq, E. Managing resistance to anti-HIV drugs: An important consideration for effective disease management. Drugs 1999, 57, 337-361.
4. Hertogs, K.; de Bethune, M.-P.; Miller, V.; Ivens, T.; Schel, P.; van Cauwenberghe, A.; van den Eynde, C.; van Gerwen, V.; Azijn, H.; van Houtte, M. A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type I isolates form patients treated with antiretroviral drugs. Antimicrob. Agents Chemother. 1998, 42, 269-276.
5. Walter, H.; Schmidt, B.; Korn, K.; Vandamme, A. M.; Harrer, T.; Überla, K. Rapid, Phenotypic HIV-1 drug sensitivity assay for protease and reverse transcriptase inhibitors. J. Clin. Virol. 1999, 13, 71-80.
6. Mahalingam, B.; Boross, P.; Wang, Y.-F.; Louis, J. M.; Fischer, C. C.; Tozser, J.; Harrison, R. W.; Weber, I. T. Combining Mutations in HIV-1 Protease to Understand Mechanisms of Resistance. Proteins 2002, 48, 107-116.
7. Tisdale, M.; Kemp, S. D.; Parry, N. R.; Larder, B. A. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc. Natl. Acad. Sci. U.S.A. 1993, 90, 5653-5656.
8. Schmidt, B.; Walter, H.; Moschik, B.; Paatz, C.; van Vaerenbergh, K.; Vandamme, A. M.; Schmitt, M.; Harrer, T.; Überla, K.; Korn, K. Simple Algorithm derived from a geno-/phenotypic database to predict HIV-1 protease inhibitor resistance. Aids 2000, 14, 1731-1738.
9. Ravela, J.; Betts, B. J.; Brun-Vézinet, F.; Vandamme, A. M.; Descamps, D.; Van Laethem, K.; Smith, K.; Schapiro, J. M.; Winslow, D. L.; Reid, C.; Shafer, R. W. HIV-1 Protease and Reverse Transcriptase Mutation Patterns Responsible for Discordances Between Genotypic Drug Resistance Interpretation Algorithms. J. Acquir. Immune Defic. Syndr. 2003, 33, 8-14.
10. Shafer, R. W.; Jung, D. R.; Betts, B. J. Human immunodeficiency virus type 1 reverse transcriptase and protease mutation search engine for queries. Nat. Med. 2000, 6, 1290-1292.
11. Drâghici, S.; Potter, R. B. Predicting HIV drug resistance with neural networks. Bioinformatics 2002, 19, 98-107.
12. Wang, D. J.; Larder, B. A.; Revell, A.; Harrigan, R.; Montaner, J. A neural network model using clinical cohort data accurately predicts virological response and identifies regimens with increased probability of success in treatment failures. Antiviral Ther. 2003, 8, S112.
13. Beerenwinkel, N.; Schmidt, B.; Walter, H.; Kaiser, R.; Lengauer, T.; Hoffman, D.; Korn, K.; Selbig, J. Quantitative phenotype prediction by support vector machines. Antiviral Ther. 2002, 7, S97.
14. Beerenwinkel, N.; Kaiser, R.; Schmidt, B.; Walter, H.; Korn, K.; Hoffmann, D.; Lengauer, T.; Selbig, J. Clustering resistance factors: Identification of complex categories of drug resistance. Antiviral Ther. 2001, 6(S1), 105.
15. Beerenwinkel, N.; Kaiser, R.; Rahnenführer, J.; Däumer, M.; Hoffmann, D.; Selbig, J.; Lengauer, T. Tree models for the evolution of drug resistance 2003, XII International HIV Drug Resistance Workshop: Basic Principles and Clinical Implications, Abstract97, Los Cabos, Mexico.
16. Beerenwinkel, N.; Schmidt, B.; Walter, H.; Kaiser, R.; Lengauer, T.; Hoffmann, D.; Korn, K.; Selbig, J., Diversity and complexity of HIV-1 drug resistance: A bioinformatics approach to predicting phenotype from genotype. Proc. Natl. Acad. Sci. U.S.A. 2002, 99, 8271-8276.
17. Sevin, A. D.; DeGruttola, V.; Nijhuis, M.; Schapiro, J. M.; Foulkes, A. S.; Para, M. F.; Boucher, C. A. Methods for investigation of the Relationship between Drug-Susceptibility Phenotype and Human Immunodeficiency Virus Type 1 Genotype with Applications to AIDS Clinical Trials Group 333. J. Infect. Dis. 2000, 182, 59-67.
18. Wang, W.; Kollman, P. A. Computational study of protein specificity: The molecular basis of HIV-1 protease drug resistance. Proc. Natl. Acad. Sci. U.S.A. 2001, 98, 14937-14942.
19. Schapira, M.; Totrov, M.; Abagyan, R. Prediction of the binding energy of small molecules, peptides and proteins. J. Mol. Recogn. 1999, 12, 177-190.
20. Rose, B.; Craik, C. S.; Stroud, R. M. Domain flexibility in Retroviral Proteases: Structural Implications for Drug Resistant Mutations. Biochemistry 1998, 37, 2607-2621.
21. Mahalingam, B.; Louis, J. M.; Hung, J.; Harrison, R. W.; Weber, I. T. Structural Implications of Drug-Resistant Mutants of HIV-1 Protease: High-Resolution Crystal Structures of the Mutant Protease/Substrate Analogue Complexes. Proteins: Struct. Funct. Genet. 2001, 43, 455-464.
22. Piana, S.; Carloni, P.; Rothlisberger, U. Drug resistance in HIV-1 protease: Flexibility assisted mechanism of compensatory mutations. Protein Sci. 2002, 11, 2393-2402.
23. Chen, Y. Z.; Gu, X. L.; Cao, Z. W. Can an optimization/scoring procedure in ligand-protein docking be employed to probe drug-resistant mutations in proteins? J. Mol. Graph. Model. 2001, 19, 560-670.
24. Shenderovich, M. D.; Kagan, R. M.; Heseltine, P. N.; Ramnarayan, K. Structure-based phenotype predicts HIV-1 protease inhibitor resistance. Protein Sci. 2003, 12, 1706-1718.
25. Vinkers, H. M.; De Jonge, M. R.; Daeyaert, F. D.; Heeres, J.; Koymans, L. M. H.; van Lenthe, J. H.; Lewi, P. J.; Timmerman, H.; Janssen, P. A. J. Inhibition and substrate recognition-a computational approach applied to HIV protease. J. Comput. Aided Mol. Des. 2003, 17, 567-581.
26. Stoffler, D.; Sanner, M. F.; Morris, G. M.; Olson, A. J.; Goodsell, D. S. Evolutionary Analysis of HIV-1 Protease Inhibitors: Methods for Design of Inhibitors That Evade Resistance. Proteins: Struct. Funct. Genet. 2002, 48, 63-74.
27. Aqvist, J.; Medina, C.; Samuelson, J. E. A new method for predicting binding affinity in computer-aided drug design. Protein Eng. 1994, 7, 385-391.
28. De Jonge, M. R.; Koymans, L. M. H.; Vinkers, H. M.; Daeyaert, F. D. Structure based activity prediction of HIV-1 reverse transcriptase inhibitors. J. Med. Chem. 2004, submitted.
29. Chen, X.; Tropsha, A. Relative binding free energies of peptide inhibitors of HIV-1 protease: The influence of the active site protonation state. J. Med. Chem. 1995, 38, 42-48.
30. Prabu-Jeyabalan, M.; Nalivaika, E.; Schiffer, C. A. How Does a Symmetric Dimer Recognize an Asymmetric Substrate? A Substrate Complex of HIV-1 Protease. J. Mol. Biol. 2000, 301, 1207-1220.
31. Kim, E. E.; Baker, C. T.; Dwyer, M. D.; Murcko, M. A.; Rao, B. G.; Tung, R. D.; Navia, M. A. Crystal Structure of HIV-1 protease in complex with VX-478, a portent and orally bioavailable inhibitor of the enzyme. J. Am. Chem. Soc. 1995, 117, 1181-1182.
32. Halgren, T. A. Merck molecular force field. I. Basis, form, scope, parametrization, and performance of MMFF94. J. Comput. Chem. 1996, 17, 450-619.
33. Halgren, T. A. MMFF94s option for energy minimization studies. J. Comput. Chem. 1999, 17, 720-729.
34. Hertogs, K.; de Bethune, M.-P.; Miller, V.; Ivens, T.; Schel, P.; van Cauwenberghe, A.; van den Eynde, C.; van Gerwen, V.; Azijn, H.; van Houtte, M. A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type I isolates form patients treated with antiretroviral drugs. Antimicrob. Agents Chemother. 1898, 42, 269-276.
35. Mahalingam, B.; Louis, J. M.; Hung, J.; Harrison, R. W.; Weber, I. T. Structural Implications of Drug-Resistant Mutants of HIV-1 Protease: High-Resolution Crystal Structures of the Mutant Protease/Substrate Analogue Complexes. Proteins 2001, 43, 455-464.
36. SAS is a registered trademark of SAS institute Inc., Cary, NC.
37. Stanford HIV Drug Resistance Database, http://hivdb.stanford.edu/cgi-bin/ PIResiNote.cgi.